Author:
Karim Sajjad,Al-Maghrabi Jaudah A.,Farsi Hasan M. A.,Al-Sayyad Ahmad J.,Schulten Hans-Juergen,Buhmeida Abdelbaset,Mirza Zeenat,Al-boogmi Alaa A.,Ashgan Fai T.,Shabaad Manal M.,NourEldin Hend F.,Al-Ghamdi Khalid B. M.,Abuzenadah Adel,Chaudhary Adeel G. A.,Al-Qahtani Mohammed H.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference69 articles.
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
2. Mirza Z, Schulten HJ, Farsi HM, Al-Maghrabi JA, Gari MA, Chaudhary AG, Abuzenadah AM, Al-Qahtani MH, Karim S. Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics. PLoS One. 2015;10(3):e0119765.
3. Bhatt JR, Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol. 2014;11(9):517–25.
4. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32.
5. Xue S, Li QW, Che JP, Guo Y, Yang FQ, Zheng JH. Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(4):3765–74.